Stock-Based Compensation

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

The Amended and Restated Omnibus Stock and Performance Compensation Plan (the “Omnibus Plan”) permits the issuance of up to 1,500,000 shares of the Company’s common stock in the form of stock options, SARs, restricted stock, restricted stock units and performance awards. The Company may issue shares out of treasury stock for these awards. During the six months ended June 30, 2022, 58,888 restricted shares, 57,542 performance-based restricted shares, and no SARs were granted under the Omnibus Plan. Stock-based compensation expense for the three months ended June 30, 2022 and 2021 was $2,082,000 and $826,000, respectively, and $3,172,000 and $1,519,000 for the six months ended June 30, 2022 and 2021, respectively.

Restricted Stock

Restricted shares granted to Company employees are amortized to expense over a three-year cliff vesting period. Restricted shares granted to members of the Board of Directors are amortized to expense over a one-year service period, with the exception of those shares granted in lieu of cash payments for retainer fees which are expensed in the period earned.

As of June 30, 2022, the total unrecognized compensation expense related to non-vested restricted shares was $2,658,000, and the related weighted-average period over which it is expected to be recognized is approximately 0.86 years.

Following is a summary of the activity of the Company's restricted stock for the six months ended June 30, 2022, with total shares and weighted-average fair value:


	Six Months Ended June 30, 2022
	Shares	Fair Value
Balance at December 31, 2021	165,553	$	44.81
Granted	58,888	39.43
Vested	(23,316)	48.85

Balance at June 30, 2022	201,125	$	42.77

Performance-Based Restricted Stock

The Company has granted three-year performance-based restricted stock (“PBRS”) awards which are contingent upon the Company’s achievement of pre-established financial goals over a three-year cliff vest period. The number of shares issued ranges from 0% to 150% of the target opportunity based on the actual achievement of financial goals for the three-year performance period.

Following is a summary of the activity of the PBRS for the six months ended June 30, 2022, based on 100% of target value:


	Six Months Ended June 30, 2022
	Shares	Fair Value
Balance at December 31, 2021	116,543	$	46.79
Granted	57,542	39.58
Vested	(34,066)	49.05

Balance at June 30, 2022	140,019	$	43.19

The PBRS that vested during the six months ended June 30, 2022 were based on the Company's achievement of 52.9% of target financial goals, resulting in the issuance of 18,021 shares of common stock. The outstanding PBRS at June 30, 2022 will vest at scheduled vesting dates and the actual number of shares of common stock issued will range from 0% to 150% of the target opportunity based on the actual achievement of financial goals for the respective three-year performance period.

SARs

There were no SARs granted and no expense recognized during the six months ended June 30, 2022. Following is a summary of the activity of the Company’s SARs program for the six months ended June 30, 2022:


	Shares	Weighted- Average Exercise Price		Average Remaining Contractual Term Years	Aggregate Intrinsic Value (In thousands)
Balance at December 31, 2021	117,089	$	34.91	1.21	$	741
Exercised	(23,976)	27.78		—	—

Exercisable at June 30, 2022	93,113	$	36.75	0.91	$	118

There were no non-vested SARs at June 30, 2022.